Industry Pipeline

June 2010
Ocular Surgery News;6/25/2010, Vol. 28 Issue 12, p52
Academic Journal
The article presents update on pre-market ophthalmic drug approvals by the U.S. Food and Drug Administration, including the granting of orphan drug status to Advanced Cell Technology Inc. for its MA09-hRPE cells for the treatment of Stargardt's macular dystrophy, Allergan's Acuvail and Ozurdex.


Related Articles

  • AzaSite Gets FDA Nod of Approval.  // Review of Optometry;5/15/2007, Vol. 144 Issue 5, p10 

    The article reports that the U.S. Food and Drug Administration has approved AzaSite, an ophthalmic solution used for the treatment of bacterial conjunctivitis. In this article, two phase three clinical trials were presented. It is noted that AzaSite uses a drug delivery system that lengthens its...

  • New indications.  // Formulary;Apr2003, Vol. 38 Issue 4, p189 

    Reports on the U.S. Food and Drug Administration's approval of xalatan, an intraocular pressure eye drop. Efficacy; Safety; Dosing.

  • Industry Pipeline.  // Ocular Surgery News;1/25/2010, Vol. 28 Issue 2, p38 

    This section offers news briefs on drug applications and approvals in the U.S. ophthalmic industry as of January 25, 2010. The iFS advanced femtosecond laser from Abbott Medical Optics has been cleared by the Food and Drug Administration (FDA). Drug applications awaiting approval include the...

  • FDA actions in brief.  // Formulary;Oct2009, Vol. 44 Issue 10, p291 

    The article provides information on various drugs approved by the U.S. Food and Drug Administration (FDA). Levocetirizine was approved for treating perennial allergic rhinitis. Bepotastine besilate ophthalmic solution was approved for treating itching in allergic conjunctivitis. Valganciclovir...

  • FDA Panel Endorses Amgen's Enbrel for Psoriasis in Children. Young, Donna // BioWorld Today;6/19/2008, Vol. 19 Issue 119, p1 

    This article reports on the decision of the U.S. Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee to approve Enbrel, a tumor necrosis factor blocker developed by Amgen Inc. The drug is used to treat moderate to severe plaque psoriasis in pediatric patients ....

  • Industry Pipeline.  // Ocular Surgery News;6/25/2014, Vol. 32 Issue 12, p34 

    This section offers news briefs on the ophthalmology industry. Recent approvals of the U.S. Food and Drug Administration (FDA) include ReSure sealant from Ocular Therapeutix, and abbreviated new drug application of bromfenac ophthalmic solution. A 501(k) clearances was issued by FDA for CEM-530...

  • Ranibizumab fast-track designation denied; Genentech plans to file complete application.  // Ophthalmology Times;9/15/2005, Vol. 30 Issue 18, p12 

    Reports on the plans of Genentech Inc. to file a complete Biologics License Application for its ranibizumab treatment for the wet form of age-related macular degeneration (AMD) in the United States in December 2005. Decision of the Food and Drug Administration (FDA) to deny a request for...

  • FDA Approves Iquix.  // Review of Optometry;12/15/2007 Part 1 of 2, Vol. 144 Issue 12, p6 

    The article reports on the approval of Iquix, a levofloxacin ophthalmic solution from Vistakon Pharmaceuticals LLC, by the U.S. Food and Drug Administration (FDA). It was stated that the medicine is an anti-infective solution for treating corneal ulcers. According to the company, Iquix is...

  • Industry Pipeline.  // Ocular Surgery News;11/25/2009, Vol. 27 Issue 22, p52 

    This section offers news briefs related to the ophthalmic medicine as of November 25, 2009. The U.S Food and Drug Administration (FDA) has approved Akorn's generic formulation of diclofenac sodium ophthalmic solution 0.1% for treating postoperative inflammation from ocular surgery. Bepreve was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics